Les tests de diagnostic de la COVID-19 du Groupe restent en mesure de détecter toutes les souches répertoriées du virus

Paris, France et Camberley, Royaume-Uni – 21 décembre 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), spécialiste mondial du diagnostic clinique, annonce que suite à la découverte par le consortium scientifique britannique COVID-19 Genomics UK d’une nouvelle mutation du virus de la COVID-19, connue sous le nom de VUI-202012/01, le Groupe a effectué une analyse

Visit Page

COVID-19 diagnostic tests remain able to detect all published virus strains

Paris, France and Camberley, UK – 21 December 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that following the detection of a new variant of COVID-19 by the UK’s COVID-19 Genomics UK consortium, known as VUI-202012/01, the Company has carried out a detailed analysis of the mutations in

Visit Page

Development of three tests for new strains of COVID-19 and avian influenza

Paris, France and Camberley, UK – 14 December 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of its research-use-only (RUO) polymerase chain reaction (PCR) test for a new strain of COVID-19 and the development of two new RUO PCR tests for avian influenza following recent outbreaks

Visit Page